.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Colorcon
Chubb
Medtronic
Accenture
US Army
Cantor Fitzgerald
Moodys
Farmers Insurance
Cipla

Generated: June 28, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,851,229

« Back to Dashboard

Claims for Patent: 4,851,229

Title: Composition comprising a therapeutic agent and a modulating agent
Abstract:An osmotic delivery system is disclosed for delivering a useful agent at a controlled and constant rate modulated by a pulsed delivery of the useful agent to an environment of use.
Inventor(s): Magruder; Paul R. (Palo Alto, CA), Barclay; Brian (Menlo Park, CA), Wong; Patrick S. L. (Hayward, CA), Theeuwes; Felix (Los Altos, CA)
Assignee: ALZA Corporation (Palo Alto, CA)
Application Number:07/150,124
Patent Claims: 1. A composition useful for producing a pulsed rate of delivery of a therapeutic agent from an osmotic device, said composition comprising a therapeutic agent and a modulating agent that dissolves in aqueous fluid and forms a solution, which modulating agent is a different agent than the therapeutic agent, said modulating agent a member selected from the group of modulating agents consisting of a solid organic acid, an inorganic salt, and an organic salt, said modulating agent present relative to said therapeutic agent in an amount less than the amount needed to maintain saturation in aqueous fluid that enters the osmotic device and wets the composition, thereby letting the concentration of the therapeutic agent increase in the aqueous fluid that enters the osmotic device and produce a pulsed rate of delivery of therapeutic agent from the osmotic device.

2. The composition useful for producing a pulsed rate of delivery of a therapeutic agent from an osmotic device according to claim 1, wherein the therapeutic agent is salbutamol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
Chubb
Healthtrust
Covington
Harvard Business School
Argus Health
Accenture
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot